Aclaris Therapeutics Inc (NASDAQ: ACRS) is 20.00% higher on its value in year-to-date trading and has touched a low of $0.59 and a high of $11.12 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ACRS stock was last observed hovering at around $1.18 in the last trading session, with the day’s gains setting it 0.08%.
Currently trading at $1.26, the stock is 2.44% and 4.03% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.29 million and changing 6.78% at the moment leaves the stock -73.49% off its SMA200. ACRS registered -84.52% loss for a year compared to 6-month loss of -81.00%. The firm has a 50-day simple moving average (SMA 50) of -$0.94 and a 200-day simple moving average (SMA200) of $0.25.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 5.00% gain in the last 1 month and extending the period to 3 months gives it a 20.00%, and is 5.88% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.16% over the week and 8.73% over the month.
Aclaris Therapeutics Inc (ACRS) has around 91 employees, a market worth around $89.36M and $31.25M in sales. Profit margin for the company is -283.15%. Distance from 52-week low is 113.49% and -88.67% from its 52-week high. The company has generated returns on investments over the last 12 months (-55.21%).
Aclaris Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.29 with sales reaching $1.37M over the same period.The EPS is expected to grow by 19.95% this year, but quarterly earnings will post -82.10% year-over-year.
155 institutions hold shares in Aclaris Therapeutics Inc (ACRS), with institutional investors hold 98.71% of the company’s shares. The shares outstanding are 70.89M, and float is at 64.48M with Short Float at 7.94%. Institutions hold 95.98% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 5.91 million shares valued at $7.44 million. The investor’s holdings represent 8.33% of the ACRS Shares outstanding. As of Dec 30, 2023, the second largest holder is Citadel Advisors Llc with 5.39 million shares valued at $6.79 million to account for 7.60% of the shares outstanding. The other top investors are Vanguard Group Inc which holds 4.72 million shares representing 6.66% and valued at over $5.95 million, while Bain Capital Life Sciences Investors, LLC holds 4.93% of the shares totaling 3.5 million with a market value of $4.41 million.
Aclaris Therapeutics Inc (ACRS) Insider Activity
The most recent transaction is an insider purchase by Powell Andrew Kenneth William, the company’s Director. SEC filings show that Powell Andrew Kenneth William bought 6,000 shares of the company’s common stock on Mar 04 ’24 at a price of $1.25 per share for a total of $7500.0. Following the purchase, the insider now owns 28863.0 shares.
Aclaris Therapeutics Inc disclosed in a document filed with the SEC on Mar 01 ’24 that Powell Andrew Kenneth William (Director) bought a total of 8,500 shares of the company’s common stock. The trade occurred on Mar 01 ’24 and was made at $1.23 per share for $10455.0. Following the transaction, the insider now directly holds 22863.0 shares of the ACRS stock.
Still, SEC filings show that on Oct 23 ’23, Monahan Joseph (Chief Scientific Officer) disposed off 6,000 shares at an average price of $5.08 for $30460.0. The insider now directly holds 129,724 shares of Aclaris Therapeutics Inc (ACRS).
